February 15, 2017 / 1:16 PM / 6 months ago

BRIEF-Selecta Biosciences announces preclinical data

Feb 15 (Reuters) - Selecta Biosciences Inc :

* Selecta Biosciences announces preclinical data showing SVP-rapamycin's potential benefit in treatment of pompe disease

* Selecta Biosciences-data suggest co-administration of antigen-specific immune tolerance therapy could induce immune tolerance to ERT alglucosidase alfa Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below